Third Harmonic Bio to Participate in the Jefferies Global Healthcare Conference
28 mai 2024 16h05 HE
|
Third Harmonic Bio
SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal,...
Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update
15 mai 2024 08h05 HE
|
Third Harmonic Bio
U.S. FDA clears Investigational New Drug application for THB335 Phase 1 SAD/MAD clinical trial initiated and subject screening underway, with results expected during 1H’25 Strengthened leadership...
Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors
28 mars 2024 08h30 HE
|
Third Harmonic Bio
SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today...
Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results
26 mars 2024 08h05 HE
|
Third Harmonic Bio
U.S. IND filed for THB335 with anticipated clinical trial start during 2Q’24 Strong financial position with cash and cash equivalents totaling $269.1 million as of December 31, 2023 SAN FRANCISCO,...
Third Harmonic Bio to Participate in the 44th Annual TD Cowen Health Care Conference
26 févr. 2024 16h00 HE
|
Third Harmonic Bio
SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today...
Third Harmonic Bio Appoints Christopher Murphy as Chief Financial and Business Officer and Provides Business Update
04 janv. 2024 08h00 HE
|
Third Harmonic Bio
Chris brings extensive enterprise-level leadership experience in business development, commercial operations, and corporate strategy IND-enabling toxicology studies of THB335 nearing completion;...
Third Harmonic Bio Announces Third Quarter 2023 Financial Results
09 nov. 2023 08h30 HE
|
Third Harmonic Bio
On track to file a U.S. Investigational New Drug (IND) application for THB335 and initiate clinical studies in 1H’24 Strong financial position with cash and cash equivalents totaling $273.9...
Third Harmonic Bio Announces Leadership Changes
31 oct. 2023 08h30 HE
|
Third Harmonic Bio
SAN FRANCISCO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today...
Third Harmonic Bio to Participate in the Morgan Stanley Global Healthcare Conference
31 août 2023 08h30 HE
|
Third Harmonic Bio
SAN FRANCISCO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today...
Third Harmonic Bio Announces Second Quarter 2023 Financial Results
10 août 2023 08h10 HE
|
Third Harmonic Bio
Introduced next-generation oral KIT inhibitor product candidate THB335, which retains the potency and selectivity of first-generation oral KIT inhibitor, THB001, with differentiated metabolic,...